Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02022644 · ClinicalTrials.gov registry record · Phase 1
Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02022644 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 18 participants.
The verdict
NCT02022644, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a single center, dose-toleration study designed to investigate and determine the maximum tolerated dose of nanoliposomal irinotecan in adults with recurrent high-grade glioma when administered directly into the tumor using a process called convection-enhanced delivery (CED).
Interventions
- DRUG nanoliposomal irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-10-23 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02022644
The ClinicalTrials.gov registry entry for NCT02022644 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nanoliposomal irinotecan is the first listed.
NCT02022644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02022644 about?
NCT02022644 is a clinical study titled "Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma". This is a single center, dose-toleration study designed to investigate and determine the maximum tolerated dose of nanoliposomal irinotecan in adults with recurrent high-grade glioma when administered directly into the tumor using a process called convection-enhanced delivery (CED).
What is the current status of trial NCT02022644?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-10-23. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT02022644?
The interventions under investigation include: nanoliposomal irinotecan (DRUG).
Who is sponsoring clinical trial NCT02022644?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.